Journal of Clinical Endocrinology & Metabolism, Vol 78, 955-959, Copyright © 1994 by Endocrine Society

ARTICLES

Markers of bone turnover in hyperthyroidism and the effects of treatment

P Garnero, V Vassy, A Bertholin, JP Riou and PD Delmas
INSERM U-403, Lyon, France.

Serum osteocalcin (OC) and bone-specific alkaline phosphatase (B-ALP), reflecting bone formation, and urinary pyridinoline cross-link (Pyr) excretion, reflecting bone resorption, have been measured in 27 patients with hyperthyroidism and 30 age-matched controls using direct and novel immunoassays. Hyperthyroid patients had higher (P < 0.001) levels of all 3 markers compared with control values: Pyr, 246 +/- 181 nmol/mmol creatinine vs. 40 +/- 12 (+515%); OC, 55 +/- 23 vs. 23 +/- 7.4 micrograms/L (+139%); and B-ALP, 22 +/- 17 vs. 10.0 +/- 5.0 micrograms/L (+120%). OC and Pyr levels were elevated above the normal range in most patients and were significantly correlated with serum free T3 concentrations (r = 0.53; P < 0.01 and r = 0.76; P < 0.001; for OC and Pyr, respectively). B-ALP levels were elevated in 11 of the 27 patients and did not correlate with serum thyroid hormone concentrations. After therapy for hyperthyroidism, Pyr and OC levels returned to normal within 1 month, whereas B-ALP transiently increased after 1 month before falling to baseline levels. The relapse of hyperthyroidism observed in 1 patient was associated with a steep increase in bone markers. These results indicate that Pyr, measured using a new and convenient immunoassay, is a highly sensitive marker for altered bone metabolism in hyperthyroidism. The increases in OC and B-ALP were less impressive, suggesting an imbalance between resorption and formation with subsequent rapid bone loss in untreated hyperthyroidism. OC and B-ALP also appear to reflect different aspects of osteoblast metabolism during the treatment of hyperthyroid patients.

This article has been cited by other articles:

				H. Pantazi and P. D. Papapetrou Changes in Parameters of Bone and Mineral Metabolism during Therapy for Hyperthyroidism J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1099 - 1106. [Abstract] [Full Text]

				R. C. Pereira, V. Jorgetti, and E. Canalis Triiodothyronine induces collagenase-3 and gelatinase B expression in murine osteoblasts Am J Physiol Endocrinol Metab, September 1, 1999; 277(3): E496 - E504. [Abstract] [Full Text] [PDF]

				H.-S. J. Ju, S. Leung, B. Brown, M. A. Stringer, S. Leigh, C. Scherrer, K. Shepard, D. Jenkins, J. Knudsen, and R. Cannon Comparison of analytical performance and biological variability of three bone resorption assays Clin. Chem., September 1, 1997; 43(9): 1570 - 1576. [Abstract] [Full Text] [PDF]

				E. Jodar, M. Munoz-Torres, F. Escobar-Jimenez, M. Quesada, J. D. Luna, and N. Olea Antiresorptive Therapy in Hyperthyroid Patients: Longitudinal Changes in Bone and Mineral Metabolism J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1989 - 1994. [Abstract] [Full Text] [PDF]

				A. Siddiqi, J. M. Burrin, K. Noonan, I. James, D. F. Wood, C. P. Price, and J. P. Monson A Longitudinal Study of Markers of Bone Turnover in Graves' Disease and Their Value in Predicting Bone Mineral Density J. Clin. Endocrinol. Metab., March 1, 1997; 82(3): 753 - 759. [Abstract] [Full Text] [PDF]

				P. Lakatos, J. Foldes, C. Horvath, L. Kiss, A. Tatrai, I. Takacs, G. Tarjan, and P. H. Stern Serum Interleukin-6 and Bone Metabolism in Patients with Thyroid Function Disorders J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 78 - 81. [Abstract] [Full Text] [PDF]

				O. Arisaka, A. Hosaka, H. Arai, S. Fujiwara, R. Tadokoro, and K. Yabuta Graves' disease associated with exophthalmos, cerebral ventricular dilatation and accelerated growth Arch. Dis. Child., January 1, 1997; 76(1): 62 - 64. [Abstract] [Full Text]